cyrilzakka/clinical-trials huggingface dataset:
Narrative Exposure Therapy for Adults With an Intellectual Disability

The goal of this naturalistic single case series design is to investigate if an adapted Narrative Exposure Therapy protocol can be effective, is feasible, and acceptable for adults with a mile learning disability.

Participants will be complete three baseline sessions before taking part in Narrative Exposure Therapy using a manual that has been adapted for people with a learning disability. Trauma symptoms will be measured weekly using the Impact of Events scale adapted for intellectual disabilities. The person's carer will also complete an informant scale related to these symptoms (LANTS-IV). The client will also complete the CORE-LD at pre, and post therapy. Six weeks after the end of the intervention, the client and their carer will be invited to a feedback session to talk about how they found the intervention.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 and over
* Meet the criteria for having a mild ID as assessed by a clinical psychologist within the team
* English speaking
* Have capacity to consent
* The participant must be experiencing trauma related stress as assessed by themselves, the clinical psychologist and the research team
* Be able to travel to one of the therapy sites
* Carer participant must have ability to reflect and comment on the trauma related stress experienced by the client participant
* Carer must also be 18 years old or older and be English speaking.
* Carer must have known participant for 1 year or more.

Exclusion Criteria:

* They are substance dependent
* They are currently receiving another trauma-focused intervention
* Currently an inpatient
* Carers excluded if they lack capacity to consent to take part in research
Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss

This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.


Eligibility Criteria:
Inclusion Criteria:

* Subjects must be premenopausal women older than 18 with female pattern hair loss.

Exclusion Criteria:

* Androgen excess
* Other scalp or hair disorders
* Contraindications to spironolactone treatment, especially pregnancy, electrolyte imbalances, history of breast cancer, or intake of interfering drugs
* Contraindications to minoxidil treatment, especially patients who are allergic to this treatment or have a history of low blood pressure or irregular heart beats
Effectiveness of P02 Digital Hearing Aids

To test the effectiveness of body-worn, digital hearing aids, model 02 which is developed by the National Electronics and Computer Technology Center, Thailand.

Hearing aids distribution and service system are limited accessed in hearing disabled people in developing countries. The local-made, body-worn, digital hearing aids is developed by the National Electronics and Computer Technology Center, Thailand. The effectiveness of this model will be compares with other standard body-worn, hearing aids in community elders. The functional gain, quality of sound, customers' satisfaction, and quality of life (EQ-5D, HHIE, HUI-3, IOI-HA) are main outcomes.The cost of Screening and hearing aids will be also investigated. The validity and reliability of several tools used such as the Thai-Hearing Handicap Inventory for elderly (HHIE) questionnaire, Music Test, Thai-Five Minute Hearing Test, and Khon Kaen Hearing Aids Evaluation are also studied.

Eligibility Criteria:
Inclusion Criteria:

* older than 60 years
* bilateral sensorineural hearing loss
* PTA (0.5-2 KHz) of better ear \> 40 DB but \<75 dB
* no deformity of pinna and ear canal
* new or unexperienced hearing aids user
* can communicate with Thai or local language

Exclusion Criteria:

* speech discrimination \<40%
* suspected of retrocochlear lesion
Improved and Simplified Staining Technique for Dysplasia Detection in Colitis

Comparing chromoendoscopy to a digital staining technique and White light in patients with IBD attending scheduled surveillance colonoscopy

In this study we will attempt to compare dye based chromoendoscopy to WLI (white light), NBI( Narrow Band Imaging) and TXI( Texture and Colour Enhancement Imaging). High Definition Colonoscopy is used. We aim to compare all these dye/lights to each other and find the best and simplest method to help to diagnose dysplasia more efficient and easier.

Eligibility Criteria:
Inclusion Criteria:

- Person schedules to IBD- surveillance colonoscopy.

Exclusion Criteria:

* Total Colectomy.
* Not well prepared Bowel. BBPS under 2 at any segement.
* Pregnancy.
Warming Contrast Media for Hysterosalpingography

The purpose of this study is to compare the use of warm-media with cold-media in performing hysterosalpingography (HSG).

As an essential step of the infertile work-up, hysterosalpingography remains widely used in many country since it was first reported at 1914. Although HSG is a non-invasive and safety procedure, it still has some adverse. Lower abdominal pain and vasovagal episodes are mainly acute reactions to the contrast media of HSG, the later include nausea, Vomit, Sweating, Weakness and even bradycardia, occur in 16-54% of patients undergoing HSG.

Many techniques were developed to reduce adverse reactions or alleviate the pain in using of contrast media, include previous analgesia, pretreatment with corticosteroids and using non-ionic contrast media for HSG. However, in a recently Cochrane's review, reported it lack of benefit for using any pain relief medication in HSG.

Pre-Warming the hands and instruments makes physical examination more comfortable for the patients. Local active warming can valid lessen the acute pelvic pain. Experiences from the peritoneal dialysis and the laparoscopy surgical reveal that warm dialysis solution or air insufflation can decrease the pain of operation. A randomize study on Sonohysterography (SHG), another technique for exam tubal and uterine cavity diseases, cue that warming of Echovist contrast media to body temperature is a simple and effective intervention in reducing discomfort at the time exam.Because the less volume of medium injected during the HSG and the iodine medias may have different properties to the Echovist media, whether this intervention is also valid in HSG remains unknown.

Eligibility Criteria:
Inclusion Criteria:

* infertile women who seeking for HSG testing

Exclusion Criteria:

* suspect of pregnancy
* acute low reproductive duct infection
* a known hypersensitivity to iodine
* genital bleeding
* genital malignancy
A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics and safety of HCP1704 in healthy subjects.


Eligibility Criteria:
Inclusion Criteria:

1. Age 19\~55 years in healthy volunteers
2. BMI is more than 18.5 kg/m\^2 , no more than 24.9 kg/m\^2
3. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing

Exclusion Criteria:

1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
2. Subjects who judged ineligible by the investigator
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy alisporivir (ALV; DEB025) with PEG and RBV versus placebo with PEG and RBV.


Eligibility Criteria:
Inclusion criteria:

* Chronic HCV genotype 1 viral infection
* HCV RNA ≥ 1,000 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent at screening
* Previous non-responders/relapsers to PEG and RBV after treatment for at least 12 weeks

Exclusion criteria:

* Treatment with any anti-HCV drug (whether approved or investigational) within 3 months prior to screening
* Women of child-bearing potential unless using highly effective
* Any other cause of relevant liver disease other than HCV
* Other protocol-defined inclusion/exclusion criteria may apply
Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment

This pilot randomized controlled trial is to investigate the feasibility and efficacy of cognitive rehabilitation for patients with post-COVID-19 cognitive impairment. Additionally, the study will obtain preliminary data, using rsfMRI, regarding the potential underlying connectivity networks, mediating the effect of CR on cognitive improvements.


Eligibility Criteria:
Inclusion Criteria:

* Adults ≥18 years of age
* Have a confirmed SARS-CoV-2 infection (positive PCR or are serum antibody positive \[against spike protein if unvaccinated or N-capsid peptide if vaccinated\])
* Speak English
* Have objective mild to moderate cognitive impairment, which will be defined as impairment in executive function (a z-score \>1.5 standard deviations below the normative mean) and in at least one other cognitive domain
* Endorse comfort and familiarity with technology.

Exclusion Criteria:

* No method of contact
* Major neurocognitive disorder, as defined by a score \<17 on the Montreal Cognitive Assessment (MoCA)
* History of pre-COVID-19 neurologic disease (e.g., stroke)
* History of severe head injury (as defined by loss of consciousness \>30 minutes)
* Ongoing substance use disorder (Mini International Neuropsychiatric Interview Version 7.0.2 \[MINI\] or Alcohol Use Disorders Test-Consumption \[AUDIT-C\] \>8)
* Unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and
* Contraindication for MRI (e.g., metallic/electronic implants).
* Not involved in cognitive rehabilitation/training or daily meditative practices during study enrollment
Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms

The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Esophageal Neoplasms.

By enrolling patients with unresectable Esophageal Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Esophageal Neoplasms.

Eligibility Criteria:
Inclusion Criteria:

* Esophageal Neoplasms diagnosed by positive biopsy or non-invasive criteria,
* Not suitable for surgical resection,
* Eastern Cooperative Oncology Group (ECOG) score of 0-1,
* A prothrombin time ratio \> 50%,
* Platelet count \> 80x10\^9/L,
* Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
* Able to comprehend and willing to sign the written informed consent form (ICF),
* Have a life expectancy of at least 3 months.

Exclusion Criteria:

* Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
* Any active implanted device (eg Pacemaker),
* Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
* Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
* Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.
Effect of a Multistrain Probiotic on Cold Symptoms in Healthy Patients with an History of Upper Airways Infection

The study is a double-blind randomized clinical trial which aims to evaluate the efficacy of a multi strain probiotic in human adults in controlling and improving cold symptoms and inflammatory response

Adult subjects (age 18-44) with a history of upper airways infection, will be assigned to placebo or probiotic groups and take either placebo or probiotic dietary intervention for 12 weeks. After that, a 6 weeks follow-up. The answers at: Common Cold Questionnarie (CCQ), Wisconsin Upper Respiratory Symptoms Survey-21 (WURSS-21) and quality of life score (SF-36) will be compared in the two groups. In addition, serological markers (blood count, lymphocyte subpopulation (B, T, T4, T8, NK), IFN-γ and IL-10 levels) will be evaluated over a 18 week period.

Eligibility Criteria:
Inclusion Criteria:

people who:

* are willing and capable of joining the study
* are willing of not varying their routine (lifestyle, physical activity..) during the study
* are willing of not varying their diet during the study
* are willing of using only the testing product during the study
* are willing of not using products that may interfere with the testing product
* have not recently joined similar studies
* have signed informed consent

Exclusion Criteria:

subjects:

* not filling the inclusion criteria
* with suspected or confirmed sensibility to one or more product component
* with chronic diseases (cardiovascular congenital diseases, hepatic diseases, renal disease, immunodeficiency)
* undergoing antibiotic/pharmacological treatment
* with other concomitant disease (infective, respiratory, gastrointestinal, immune)
* who underwent an immunomodulating treatment in the past 4 weeks
* who underwent an immunosuppressant therapy in the past 3 months
* with severe disease ongoing
* who abuse of alcohol and/or drugs
* who are considered not eligible by the investigator
* not able to communicate due to language barriers, mental issues or cerebral functioning impairment
Zolpidem or Exercise for Insomnia?

Introduction: The prevalence of chronic insomnia in the general population is between 10 and 15%. The therapy commonly prescribed for its treatment is pharmacological, however, there are several non-pharmacological alternatives being studied, among them physical exercise. Although some studies have described the effect of exercise on sleep in insomnia, there are no studies comparing exercise and drugs in the treatment of chronic insomnia, or its effect as coadjuvant therapy.

Objective: To compare the acute and chronic effects of aerobic exercise and zolpidem on sleep quality, mood and quality of life in patients with chronic insomnia.

Material and Methods: 30 patients with chronic insomnia will be randomly assigned into two groups: EXERCISE (n=15) or ZOLPIDEM (n=15). The patients of EXERCISE group will be included in an aerobic exercise program, performed in 50% of reserve heart rate, on a treadmill (50 minutes, 3 times/week), during 6 weeks. The ZOLPIDEM group will be treated with zolpidem (10mg/night) during 6 weeks. Polysomnography, actigraphy, sleep diary and questionnaires will be used the evaluate sleep pattern. Mood and quality of life will be investigated by POMS and SF-36 questionnaires.

Hypothesis: Considering previous studies have demonstrated positive effects of aerobic exercise in the insomnia symptoms, the hypothesis of this study is that aerobic exercise, performed at moderate intensity, can control the symptoms of chronic insomnia similarly to pharmacological therapy.


Eligibility Criteria:
Inclusion criteria:

* age 30 -60 years;
* clinical diagnosis of chronic insomnia according to the DSM-V;
* insomnia complaint at least 3 times a week for at least 3 months;
* be physically inactive (exercise less than 2 times a week).

Exclusion criteria:

* evidence that insomnia is directly related to medical conditions or side effects of medications;
* obstructive sleep apnea syndrome;
* ECG abnormalities that prevent physical exercise or use of beta-blockers;
* uncontrolled clinical diseases (diabetes, hypertension, cardiovascular, neurological or renal diseases);
* use or history of abuse of alcohol or psychoactive substances);
* use of sleeping pills\> 2 times a week;
* shift workers.
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia

To evaluate efficacy of BL33 for mild and moderate benign prostatic hyperplasia(BPH).There are trials showing that electroacupuncture on BL33 for mild and moderate BPH is more effective than terazosin. It could reduce the International Prostate Syndrome Score (IPSS) by 6.68±2.84(39.79%),lower urinary symptoms bother of score(BS) and bladder residual urine, and increase maximum urinary flow rate.But the efficacy of BL33 has not been studied. The objective of this study is to evaluate efficacy of BL32 for mild and moderate BPH by comparison with non-acupoint group.

efficacy here means specific effect(or active ingredient) of the point BL33.

Eligibility Criteria:
Inclusion Criteria:

* 50-70 years old
* Mild to moderate BPH evaluated by I-PSS
* Patients having urinary dysfunction more than 3 months
* Patients with stable life signs
* no use of α1 receptor blocker, 5α-reductase inhibitor or traditional Chinese medicine for over 1 week
* Volunteer to join this research and sign the written informed consent prior to receiving treatment

Exclusion Criteria:

* Urinary dysfunction caused by gonorrhea or urinary tract infection
* Oliguria and anuria caused by urinary calculi, prostate cancer, bladder tumor and acute/chronic renal failure
* Urinary dysfunction caused by neurogenic bladder, bladder neck fibrotic and urethral stricture
* Failure of invasive therapy for prostatic obstruction
* Injured local organs, muscle and nerve caused by pelvic operation or historical trauma
* Upper urinary obstruction and hydrocele combined with damaged renal function due to BPH diagnosed by B-ultrasound
* Patients who can't stick to treatment because of economic reason, far distance between home and the hospital or difficult walking etc.
Door-Through-Door Companion Rideshare Technology for Individuals with Alzheimer's Disease and Related Dementias (AD/ADRD)

The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD. Participants will be assigned either door-through-door (D2D) rideshare or curb-to-curb (C2C) rideshare services. he main question it aims to answer is:

Do D2D rideshare services reduce missed medical appointment rates compared to C2C rideshare services?

A pilot randomized controlled trial (Stage 1). By stratifying on levels of cognitive impairment, i.e., no cognitive impairment vs. have mild to moderate cognitive impairment/MCI or subjective cognitive decline/SCD, the research team will randomly assign 120 riders, who have scheduled medical appointments at partner practices of Onward, to one of two groups: Onward D2D service (intervention) vs. C2C rideshare (control).

Intervention Group (D2D): Door-to-Door rideshare services with a trained companion driver.

Control Group (C2C): Standard Curb-to-Curb rideshare services.

Eligibility Criteria:
Inclusion Criteria:

* All participants (or their surrogate) have the capacity to agree to allow Onward service for transportation;
* have scheduled medical appointments at partner practices of Onward;
* ages 60+
* community-dwelling;
* 60 participants who self-reported cognitive problems, such as memory issue, or have mild cognitive impairment, subjective cognitive decline, or AD/ADRD diagnosis

Exclusion Criteria:

* current enrollment in another transportation study;
* already using any type of transportation service;
* enrollees with comfort care only;
* Not wheelchair bound, e.g. if using a wheelchair must be foldable and must be able to transfer
* Transient, lacking consistent long term housing
Effect of G17DT in Patients With Stage II/III Colorectal Cancer

This Phase 2 study was an open label, single-center 18-week study to compare basal and meal stimulated plasma gastrin levels before and after treatment with 3 intramuscular injections of 250 µg G17DT, with and without the concomitant administration of Omeprazole.


Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects aged 18 to 70 years, inclusive
* Written informed consent was provided
* Histologically confirmed Stage II/III colorectal cancer after radical surgery
* A minimum of 3 months elapsed since completion of the chemotherapy for subjects who had received adjuvant chemotherapy
* Subject had recovered from any toxic effects of chemotherapy

Exclusion Criteria:

* Had a known local recurrence of colorectal cancer or presence of metastatic colorectal cancer lesions
* Was using an inadequate method of contraception (determined at the discretion of the investigator), only for women of childbearing potential who were sexually active
* Was unable to comply with the protocol
* Was unable to abstain from H2 receptor antagonists, PPIs or anticholinergics medications for 2 weeks
* Required H. pylori eradication therapy during the study
* Had prior vaccination with G17DT or any other product with a similar mechanism of action
* Had a history of gastric or vagus nerve surgery
* Had any clinically significant laboratory abnormalities and medical conditions which were unexplained, or, in the opinion of the investigator, did not allow for safe entry of the subject into the study
* Had contraindications to intramuscular injections (e.g., bleeding disorders or treatment with anticoagulants \[except for aspirin\])
* Had serious and unstable cardiovascular or respiratory disease, other malignancy or any other condition that would have jeopardized subject safety or confounded the results
* Had a known hypersensitivity to diphtheria toxoid, G17DT, any of its components or any similar compound
* Had any other condition that might have influenced the plasma gastrin level (e.g., achlorhydria, Zollinger-Ellison syndrome)
* Had used of an investigational drug within the previous month
* Had taken treatments that alter the immune response such as radiotherapy, corticosteroids, and antineoplastic drugs (Inhaled corticosteroids were permitted.)
* Had conditions that impaired the immune response (e.g., acquired immune deficiency syndrome)
* Had a history of drug or alcohol abuse within the past year
* Was unable to accept a standard breakfast for dietary reasons
Beta-thalassemia and Microparticles

The results will allow us to evaluate the role of MP in the thrombo-embolic risk observed in thalassemic patients and to underline a possible difference between TM and TI. The in vitro and in vivo study of MP in erythrocytes concentrates is a new approach to explore the consequence of transfusion in polytransfused patients. Finally, the identification of a possible relationship between the oxidative stress and the production of MP may lead to the development of specific therapeutical approaches

Microparticles (MP) are intact vesicles derived from cell membranes which arise mainly through cell membrane activation processes and from apoptosis. MP originating from platelets, endothelial cells and monocytes have been most extensively studied, though similar particles can arise from red cells and granulocytes. The ability to form microparticles is an essential part of physiological coagulation.However, MP may play an important procoagulant role in several diseases including sickle cell disease, and paroxysmal nocturnal haemoglobinuria (PNH).

Several studies reported the presence of MP in TI and their potential role in the hypercoagulable state. The investigators propose in this study to investigate the presence and origin of MP in TM patients.

Eligibility Criteria:
Inclusion Criteria:

* Patient recorded in the national register of the patients attained by beta-thalassemia (TI) or (TM)
* Patient monitoring in one of 5 recruiters centers
* Patient more than 15 years
* Patient consented and informed

Exclusion Criteria:

* Blood transfusion dating from less than 3 months for TI
* Composite Heterozygotes HbE /beta-thalassemia
* pregnant women
* other disease